India could soon get a new dengue shot. Qdenga, a dengue vaccine made by Japan-based Takeda, is set to arrive in the Indian private market in the first half of 2027, after receiving regulatory approval in the country.
Qdenga Dengue Vaccine Explained
Takeda’s Qdenga is a live attenuated dengue vaccine that provides protection against all four serotypes of the dengue virus – DENV-1, DENV-2, DENV-3 and DENV-4. The vaccine has received marketing authorisation from India’s Central Drugs Standard Control Organisation for use in individuals aged 4-60 years.
When Can India Expect To See Qdenga?
India can expect to see Qdenga in the first half of 2027, after the completion of the country-specific market and regulatory processes.
Dr Reddy’s Laboratories has inked an agreement with Takeda to market and distribute the vaccine in the private healthcare sector across India. It will be available to both children and adults within the age group specified by the drug regulator.
How Is Qdenga Administered?
Qdenga is administered as a 2-dose vaccination regimen, with the second dose being given 3 months after the first dose. The World Health Organization (WHO) also recommends a 2-dose schedule for the age groups and indications it covers, with the two shots given at least 3 months apart.
Does A Dengue Test Need To Be Taken Before Getting The Vaccine?
One of the biggest advantages of Qdenga is that individuals do not need to get themselves tested for a previous dengue infection before getting vaccinated. That said, a healthcare professional may advise differently depending on an individual’s circumstances.
What Is The Cost Of The Vaccine In India?
While the cost of the shot in India has not been disclosed yet, it is expected to target the private healthcare market at the time of its launch.
The vaccine could eventually become a part of broader dengue management and prevention strategies, but it is unlikely to replace age-old methods of avoiding mosquito bites and eliminating breeding grounds.
